SOURCES SOUGHT
65 -- General Woundcare (Sponges)
- Notice Date
- 3/26/2008
- Notice Type
- Sources Sought
- Contracting Office
- Great Plains Regional Contracting Ofc, ATTN: MCAA GP L31 9V, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200
- ZIP Code
- 78234-6200
- Solicitation Number
- DADA09-08-T9014
- Response Due
- 4/17/2008
- Archive Date
- 6/16/2008
- Point of Contact
- kevin.w.hill1, 210-292-3270
- E-Mail Address
-
Email your questions to Great Plains Regional Contracting Ofc
(kevin.w.hill1@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- A. General Information. The Central Region (6, 7 & 8), a military integrated delivery network, comprised of 42 Army, Navy, Air Force Medical Treatment Facilities (MTFs) in the states of Arizona, Arkansas, Colorado, Idaho, Kansas, Louisia na, Missouri, Oklahoma, Nebraska, Nevada, New Mexico, North Dakota, South Dakota, Texas, Utah, and Wyoming, announces a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of General Woundcare (Sponges). The primar y objective of this program is to standardize the quality of care across the region based on a best value determination that represents the clinically preferred product or source(s) at the best possible price. It is also intended that standardized product s be obtained through the DoD Prime Vendor Program. The major facilities in the region include but are not limited to: Brooke Army Medical Center, Fort Sam Houston TX; Wilford Hall Medical Center, Lackland AFB TX; Darnall Army Medical Center, Fort Hood TX; Reynolds Army Community Hospital (ACH), Fort Sill OK; William Beaumont Army Medical Center, Fort Bliss TX; 10th Medical Group, USAF Academy CO; Evans ACH, Fort Carson CO; General Leonard Wood ACH, Fort Leonard Wood MO; Irwin ACH, Fort Riley KS; 9 9th Medical Group, Nellis AFB NV, and Bayne-Jones ACH, Fort Polk LA. This standardization action is part of the Medical/Surgical Prime Vendor program executed by the Defense Supply Center Philadelphia (DSCP), Directorate of Medical Materiel. In ord er to participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the Prime Vendor for the program. This is pursuant to the DAPA clause by which DAPA holders agree to the Standardization process and to allow Prime Vendors to distribute their products. This RFRIAQ is a supplement to the Prime Vendor Program and is not a contract. For additional information regarding DSCPs Prime vendor program please access their web site at https://dmmonline.dsc p.dla.mil The resulting Regional Incentive Agreement (RIA) will be for a base period of two years (24 months) from date of selection with three12-month option periods. Anticipated selection date is July 2008. The evaluation will be based on clinica l, technical, and pricing factors. The Technical/Company and Clinical/Performance evaluation factors are considered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become mor e important. The selection will be determined utilizing Best value/ trade-off criteria. The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of MTF preference and product availability. B. Products & Performance Required. The Central Region (6, 7 & 8) is seeking product line items in the category of General Woundcare (Sponges), which at a minimum includes the high volume lines below. Within this region, this product line has an estimated annual dollar requirement of $470,812.25. This forecast is based on historical prime vendor s ales during a recent 12-month period. The top high volume usage lines for this project include: Gauze Sponges, Bulk $229,219.52; All Purpose Gauze Sponges $78,863.73; Gauze Cover Sponges/Peel Back 4 x4 Sterile $31,653.21; Gauze Sponges Sterile 4 x 4 in tr ay $7,269.05. At the request of the Central Region (6, 7 & 8) MTFs, vendors will provide on-site support and in-servicing during implementation, educational resources and tools for clinical use of the product, conversion information, prime vendor or der numbers, MSDS information, and itemization of the brands, types and packaging information of the products supplied by the vendor. C. Instructions to Vendors. INTERESTED RESPONDENTS MUST PROVIDE DETAILED HARD COPY RESPONSES TO THE TECHNICAL CRITERIA REQUIREMENTS STATED WITHIN THIS NOTICE BY 3PM CST ON 17 APRIL 2008. Vendors that fail to meet this submittal deadline will be disqualified from par ticipating. This process will include vendor requirements to provide hard copy responses to technical criteria, no charge samples for clinical evaluation, and submission of electronic best price quotes. Due to the potential for mail to be lost, v endors must confirm with the Regional Point of Contact (POC) stated below that their submission, quotes, and literature or other requested information has actually arrived at the Tri-Service Regional Business Office (TRBO). Each submitting vendor will con firm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. Responses should be sent via your preferred delivery carrier with a requested return receipt and/or tracking number to Ms. Sarah Allen, Tri-Service Regional Business Office, 7800 IH-10 West, Suite 220, San Antonio TX 78230. (ELECTRONIC SUBMISSIONS TO INITIAL ANNOUNCEMENT ARE NO LONGER ACCEPTED) Contact Ms. Sarah Allen at (210) 292-3287 prior to the closing date of this a nnouncement with any further questions. D. Evaluation Criteria. The Tri-Service Product Review Board (TPRB) is the governing body of the standardization process. This board includes clinicians and logisticians from the Military Treatmen t Facilities within the Central Region. They are the deciding officials for this initiative. Phase I Technical/Company Evaluation Process. Interested respondents are to respond to this FBO announcement by mailing their intent to participate wi th hard copies of the following information: company name, point of contact, address, phone number, fax, email address, announcement number, DAPA number and complete answers to the technical criteria to the above POC by the required response date. Vendors are required to meet/provide responses to the technical/company criteria stated below. All technical/company criteria are weighted equally. The responses will be reviewed under the purview of the CPT to determine the acceptability of each vendor. After the review of the technical/company criteria, those vendors who meet these criteria will be qualified/invited to participate in the clinical/performance evaluation. Acceptability for purposes of evaluation of technical/company criteria: Generally, r esponses to all questions in this section demonstrate: (1) the business concern submitting the quote is a distributor or manufacturer of a complete line of the subject medical/surgical consumables; (2) based on the vendors responses, the evaluators have reasonable confidence that the line or products and/or services submitted meet the medical standards of care of the community, applicable to such products or services; (3) the vendor has or is obtaining a DAPA for the items (vendors that fail to have a DAP A will be disqualified); (4) the vendor has, or is obtaining, an agreement covering the items with Cardinal Health, the Prime Vendor for the region (vendors whose products are not available through the regional PV will be disqualified); 5) the vendor inten ds to provide discounts off DAPA for all products included in this standardization initiative (vendors that fail to provide a discount from DAPA will be disqualified); 6) Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as their DAPA price. Therefore, National FSS prices do not represent a discount off the DAPA. and 7) the vendors information provided is factually correct. Any misrepresentation of information will disqualify the vendor from f urther consideration. If industry participation is unsatisfactory, the TPRB will decide whether to proceed with or delay the project. All e-mail c ommunication between vendors and the region should be digitally signed. Also, all communications of significant milestones, such as invitations to participate, notices of disqualification, etc. must be digitally signed. The vendors who meet the fol lowing technical/company criteria will be qualified/invited to participate in the clinical/performance evaluation process The following Technical/Company Evaluation Criteria have been established for this standardization initiative: 1. Vendo r must manufacture and/or distribute a complete product line of General Woundcare (Sponges). A complete line of product is defined as the MTFs requirements for usage items in the product line. Usage items are defined in the Medical/Surgical Prime Vendo r contract statement of work as DAPA items ordered at least once per month, and at least one unit per order. At a minimum, this includes: (a) All Purpose Sponges (sterile & non-sterile) (b) Bandage Gauze (sterile & non-sterile) (c) Disposable Lap Sponge s (sterile & non-sterile) (d) Sponge Surgical Gauze, Bulk 2x2s; 4x4s; 4x8s. Provide certification of all brands of this product line that you manufacturer or distribute with the initial submittal. (Note that vendors that fail to have a DAPA or show a l ack of progress in obtaining a DAPA will be disqualified.) 2. Vendors must have a DAPA or be in the process of applying for a DAPA number for the General Woundcare (Sponges) product line. Provide the DAPA number or proof of the application process with the initial submittal. (Note that vendors that fail to have a DAPA or show a lack of progress in obtaining a DAPA will be disqualified.) 3. Vendors must have a separate agreement with the regional prime vendor, Cardinal Health for distribution in this Region and provide certification of this with the initial submittal. (Note that vendors whose products are not available through the regional PV will be disqualified.) 4. Vendors must provide discounts off DAPA for all products included in this standa rdization initiative. (Note that vendors that fail to provide a discount from DAPA will be disqualified.) 5. Vendors must provide electronic and hard copy pricing quotes and a competitive product cross-reference in the prescribed electronic Microsoft E xcel format upon request. Note: All e-mail communications between vendors and the region will be digitally signed. 6. Vendor must provide educational information for Wound Care, General (Sponges) as well as no cost samples for the evaluation. 7. Vendor must provide customer service (telephonic, onsite, website or email) for regional facilities. Identify company resources and capabilities for such support with the initial submittal. 8. Vendors must have a local vendor representative available in the region. Provide contact information, i.e. name, address, phone number, and e-mail address with the initial submittal. 9. Vendors must provide any history of back orders and/or FDA or company recalls that occurred during the most recent 24-month period for the product line including dates, duration, cause, and resolution with their initial submittals. 10. All products are labeled with product description (i.e. dimensions, sterility, ply count). 11. All surgical sponges (laparotomy and gauze ) must contain a radiopaque devise. Phase II Clinical/Performance Evaluation Process: The multi-disciplinary Clinical Product Team facilitated by the TRBO will request samples (at no charge to the government) from the product line to be clinica lly evaluated at select Military Treatment Facilities. Vendors are required to ship their no cost samples directly to the designated MTFs and will be allowed 21 calendar days from the date of notification to complete the delivery. Samples must be shipped to arrive at the MTF by COB, 3PM CST, on the (21st ) calendar day after the notice to ship. Vendors failing to deliver by the deadline will be disqualified fr om further consideration in the standardization process. CPT teams will evaluate the product against the clinical/performance criteria in a clinical setting. All clinical/performance criteria are weighted equally. The clinical evaluation period is estimated to last approximately eight weeks. The CPT will evaluate the clinical/performance criteria using a Likert-like one to five rating scale where as: One (Does not meet minimum needs - worst score), Two (Meet minimum needs but is not clinically r ecommended), Three (Meet minimum needs), Four (Exceed minimum needs), Five (Provides superior clinical advantages - best score). The CPT has established a target threshold of 3.0 for the clinical acceptability of products for standardization. The CPT wil l analyze this acceptability as being at or near 3.0 depending on the break in the average scores and how closely scores are clustered near the Acceptability Target Threshold of 3.0. Subject to this review, products below this threshold will be clinically unacceptable and be disqualified from further consideration for standardization. In the pre-source selection procedures above, the CPT will determine/approve that, product educational information and sample sets are required for the evaluation. The CPT intends that clinical evaluations be conducted in a clinical setting; however, the Government reserves the right to conduct evaluations in either a non-clinical or clinical setting or both. Clinical evaluations will be tabulated by the TRBO and re sults will be forwarded to the CPT for review. Clinical/Performance evaluation is more important than the price. Based on the clinical evaluation results, the CPT will provide a vendor selection recommendation to the TPRB. Clinical/Performance Cr iteria: During the pre-source selection procedures, the CPT will evaluate products based on the equally weighted clinical/performance criteria outlined below: Minimal Clinical Acceptability Target Threshold: 3.0 1. Sponges may be cut to the desired shape without shredding/unraveling (to prevent introducing debris). 2. Sponges are highly absorbent (designed to transfer exudate from wound) 3. Products are low linting/free of foreign particles (to prevent introducing debris) P hase III Pricing Analysis Process. 1. The following elements will be considered in the pricing analysis: (a) Operational Impact of RIA prices on the Region (Post-Standardization Costs), (b) Potential Cost Avoidance, (c) Impact of Unmatched Lines, a nd (d) Impact on SKUs by each vendor. Due to the potential for Base DAPA prices to be inflated, the Impact of RIA prices on the Region is considered more important than other pricing elements. 2. Vendors that meet the 3.0 clinical acceptability tar get threshold will be qualified to submit best value pricing for analysis to the TRBO. Those vendors with results less than 3.0 will be disqualified from further consideration depending on the break in the average scores and how closely scores are cluster ed near the Acceptability Target Threshold as determined by the CPT. Vendors that have been disqualified will be notified in writing at the conclusion of the evaluation process. 3. Upon request, vendors will be given 14 calendar days from the date of request to submit their best pricing quotes, in a prescribed format, based upon the total requirements of the Central Region. The Region intends to evaluate quotes and select a vendor or vendor(s), without discussions. Vendor quotes should contain the v endor's best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendor's best responses to all technical and/or company questions listed in this announcement. Vendor quotes should contain th e vendor's best tiered-pricing discounts off of the vendor's DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Region) . Additionally, the Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. If a down-selection is made during the evaluation process, the Region may limit the number of quotes to the greatest num ber that will permit an efficient competition among vendors. 4. Those vendors that fail to respond as required will be disqualified from further consideration. 5. Upon request, vendors will forward pricing to the TRBO, and the TRBO will prepare a pri cing analysis. Pricing will be based on a committed volume for a two-year period with possible one-year option periods not to exceed a total of 5 years. 6. The Technical/Company and Clinical/Performance evaluation factors are considered significantly mo re important than cost or price. As the evaluation results become more equal, price will become more important. 7. The Central Region TPRB reviews the data for a best value decision. 8. The DSL will ensure that the prices, with discounts off the Dis tribution and Pricing Agreement (DAPA) will be a good value, in conjunction with the volume purchasing commitment, and the technical merit of the submittal. 9. The Central Region TPRB votes for the best value for a single or multiple vendors selection(s ). The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combina tion of MTF preference and product availability.
- Place of Performance
- Address: Great Plains Regional Contracting Ofc ATTN: MCAA GP L31 9V, 3851 Roger Brooke Drive Fort Sam Houston TX
- Zip Code: 78234-6200
- Country: US
- Zip Code: 78234-6200
- Record
- SN01542301-W 20080328/080326224701 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |